Parathyroid hormone-related protein (PTHrP), which is responsible for producing hypercalcemia in patients with humoral hypercalcemia of malignancy, has recently been identified in several normal tissues. Because PTHrP, like parathyroid hormone (PTH), is known to exhibit vasodilatory properties, we investigated the expression and regulation of PTHrP mRNA in cultured rat aortic smooth muscle cells (SMC). We report here that PTHrP mRNA is expressed in SMC and is markedly induced by serum in a time-and concentration-dependent fashion. Addition of 10% fetal calf serum to serum-deprived, confluent cells, resulted in a marked induction of PTHrP mRNA by 2 h with a peak at 4-6 h. PTHrP was detected in SMC by immunocytochemistry and radioimmunoassay of conditioned medium, and was shown to be up-regulated within 24 h after the addition of serum. The serum induction of PTHrP mRNA was blocked by actinomycin D and by cycloheximide indicating the need for protein synthesis to evoke the serum effect on PTHrP gene transcription. In addition, treatment with dexamethasone, which has been previously shown to reduce the constitutive expression of PTHrP in human cancer cells, also blunted the serum induction of PTHrP mRNA in SMC. Treatment of quiescent cells with the serum mitogens platelet-derived growth factor or insulin-like growth factor-I had no effect on PTHrP, whereas the vasoactive peptides endothelin, norepinephrine and thrombin stimulated PTHrP expression. Exogenous addition of recombinant had no significant effect on SMC DNA synthesis as measured by [3HJthymidine incorporation. In summary, the abundance of PTHrP mRNA and the characteristics of its regulation in SMC suggest a major role for PTHrP as a local modulator in vascular smooth muscle. (J. Clin. Invest. 1991. 88:1841-1847
Introduction
The parathyroid hormone-related protein (PTHrP)' has recently been isolated from human tumors associated with the A portion of this work has appeared in abstract form (1991. Clin. Res.
39:98A).
syndrome ofhumoral hypercalcemia ofmalignancy (1) (2) (3) . The protein shares sufficient amino-terminal homology with parathyroid hormone (PTH) that it can activate PTH receptors in target cells (4) (5) (6) and thereby cause hypercalcemia in patients harboring PTHrP-producing tumors. However, PTHrP is the product of a unique gene (7, 8) and its mRNA transcripts are present not only in tumor tissue (9, 10) but also in normal endocrine and nonendocrine tissues (1 1-13) . Although a definitive role for PTHrP in normal cell physiology has not been established, emerging evidence suggests that it might have predominantly local actions.
It is well established that both PTH and PTHrP are vasorelaxant in vivo, and vascular tissue (14) and vascular smooth muscle cells (SMG) appear to possess specific receptors for these peptides ( 14, 15) . In order to investigate further a possible role for PTHrP in vascular smooth muscle, we have studied PTHrP gene expression in cultured aortic SMC. Our studies show that PTHrP and its mRNA are expressed at relatively low abundance in serum-deprived cells, but are markedly induced after repletion of cells with serum. The magnitude and timecourse of the serum induction of PTHrP mRNA in vascular SMC suggest that PTHrP may be a locally bioactive factor involved in the paracrine control of contractility or differentiation in this tissue.
Methods
Materials. Human recombinant PTHrP [PTHrP-(l-141)] was a generous gift from William Wood, Genentech Corp., South San Franscisco, CA. Bovine parathyroid hormone (Tyr-34) 1-34 amide [PTH- )NH2] and platelet-derived growth factor (PDGF) were purchased from Bachem, Torrance CA. Insulin-like growth factor-I (IGF-I) was from Amgen, Inc., Thousand Oaks, CA, and dexamethasone (DEX), endothelin-I, thrombin, and norepinephrine were purchased from Sigma Chemical Co., St. Louis, MO. 1,25-Dihydroxyvitamin D3 [1,25- (OH)2D31 was kindly provided by Dr. Milan Uskokovic, HoffmannLaRoche, Inc., Nutley, NJ. All other reagents were molecular biological grade.
Primary smooth muscle cell cultures. Medial SMC were isolated from 200-g male Sprague-Dawley rats and cultured by the procedure described by Chamley-Campbell et al. (16) with minor modifications. Cells were isolated by removing the adventitia with forceps under a dissecting microscope and suturing the open ends of the vessel with surgical thread before enzymatic disruption. The vessels were everted and incubated in 0.1% collagenase for 15 min and then 0.1% trypsin for 15 min to remove the endothelial cell layer. The washed vessels were then treated with 0.05% elastase and 0.1% collagenase, without stirring, for 2 h at 37°C, in 95% 0J5% CO2. After digestion, the resulting tissue-cell suspension was filtered through a 100 ,M nylon mesh and the filtrate treated with 20% fetal calf serum (FCS) to inactivate the enzymes. Cells were centrifuged, and the pellet resuspended in Iscove's modified Dulbecco's minimal essential medium supplemented with 10% FCS, L-glutamine, and antibiotics as described (17) . Cells were seeded at a density of 5 X 104 cells cm-2 in 50-cm2 culture dishes and maintained at 370C in a humidified atmosphere of 95% 0215% Co2, with media changes every 2 d. Cells were passaged when confluent by treatment with a mixture of trypsin and collagenase. For these studies we used cells from passages 4 through 6 which retained phenotypic properties consistent with SMC: a hill-and-valley pattern of growth in confluent cultures, nodule formation, and specific immunocytochemical staining of a-actin.
Total RNA extraction and Northern blot analysis. Total RNA was extracted according to the method of Chirgwin et al. (18) with slight modifications. 50 gg oftotal RNA (from two confluent T-75 flasks) was electrophoresed on 1.5% agarose, formaldehyde gels containing ethidium bromide. RNA samples were transferred onto nylon membranes and then hybridized to a PTHrP cDNA probe (rPLPm9) labeled with [32P]CTP by a random primer method (19) . The cDNA probe encodes most of the coding region and the 3'-untranslated region of rat PTHrP (10) . In some cases the blots were reprobed with a c-myc cDNA probe (pHSR-1, provided by J. M. Bishop, University ofCalifornia, San Francisco), or a cDNA probe for rat cyclophilin (BamHI restriction fragment from plasmid pCD1 5.8.1 [20] [3H]thymidine (1 ,Ci/ml) was added to each well and its incorporation into trichloroacetic acid-precipitable DNA was determined after 6 h by liquid scintillation counting.
Immunocytochemistry ofPTHrP. Cells were rinsed with PBS and fixed in 4% phosphate-buffered paraformaldehyde for 1 h. Fixed cells were washed twice with 0.1 M Tris, pH 7.5, and then subjected to an indirect, immunoperoxidase cytochemical procedure as described (21, 22) . In brief, monolayers were incubated overnight with an affinity purified monoclonal antibody against PTHrP (Oncogene Science, Manhassett, NY). Cells were then reacted with 1 Ag/ml of peroxidaseconjugated anti-mouse IgG for 1 h at room temperature and developed with 0.05% 3,3'-diaminobenzidine tetrahydrochloride (PolySciences, Inc., Warrington, PA) with 0.3% glucose oxidase, 0.4 mg/ml ammonium chloride, and 2 mg/mI D(+)glucose. Control monolayers were incubated with a nonimmune mouse IgG in place of the primary antibody.
Radioimmunoassay ofPTHrP. PTHrP was measured in SMC conditioned medium before and after serum exposure using a radioimmunoassay. Confluent cells in 12-well cluster plates were deprived of serum for 5 d then exposed to 10% FCS for various times up to 24 h.
Conditioned medium (200 Al) was removed and assayed for PTHrP using a commercial kit (INCStar, Stillwater, MN) with one modification. The standard PTHrP-(1-34) was diluted in culture medium containing 10% FCS in place of the standard diluent. Fetal calf serum was added to conditioned medium from serum-free cultures to give a final concentration of 10%. The limit ofdetection ofthis assay was 1.8 (Fig. 1) . PTHrP mRNA levels were maximal at 4 h and fell rapidly thereafter. By 8 h PTHrP mRNA expression persisted at a level slightly above that observed under serum-free conditions (Fig. 1) . To further characterize the early phase ofPTHrP mRNA induction we compared the time course of c-myc mRNA expression, a gene known to be rapidly induced by serum in SMC (24) , by reprobing the same blot with a human c-myc cDNA probe. Serum stimulated c-myc mRNA to maximum levels by 1 h as compared to the later peak (4 h) observed for PTHrP mRNA expression (Fig. 1) (Fig. 3) . These data suggest that the acute serum induction of PTHrP depends on new protein synthesis, whereas the constitutive expression of the gene (at least through 6 h) does not.
To further confirm the effectiveness ofthe inhibitors in this experiment, the same blot was reprobed with a c-myc cDNA probe (Fig. 3, middlepanel) . As expected, actinomycin D eliminated the serum induction ofc-myc mRNA whereas cycloheximide treatment resulted in a progressive increase in c-myc mRNA content above that observed by addition of serum alone. This effect has been demonstrated previously in aortic SMC (24) (Fig. 5) .
Several vasoactive peptides were also tested for their effects on PTHrP mRNA expression in serum deprived SMC. Endothelin (10-' M) markedly induced PTHrP mRNA to levels approaching those observed in serum-treated cells (Fig. 6 ).
Thrombin (1 U/ml) and norepinephrine (10-' M) also induced 4' PTHrP mRNA above serum-free levels but were less effective than endothelin.
Immunochemical detection ofPTHrP in SMC. PTHrP was detected in SMC using immunocytochemistry and was shown to be induced by serum. Addition of 10% FCS to serum-deprived cells was associated with an increase in immunostaining relative to cells maintained in serum-free medium (Fig. 7) . Detectable increases in PTHrP-like immunoreactivity were evident 16-24 h after addition of serum.
PTHrP accumulation in medium from serum treated SMC was also detected by radioimmunoassay (Fig. 8) . Concentrations rose from undetectable levels (< 1.8 pmol/liter) in serumdeprived cells to peak levels of 4-5 pmol/liter by 12 h. Similar results were obtained in a separate experiment.
Effect ofPTHrP on SMC DNA synthesis. To investigate the potential influence of PTHrP on SMC proliferation we determined the effect of exogenous peptide on DNA synthesis. Recombinant PTHrP(1-141) added to serum-deprived cells at 1, 10, and 100 ng/ml for 18 h had no significant effect on [3H]-thymidine incorporation (Fig. 9) . By contrast, addition of medium containing 10% FCS significantly (P < 0.001) increased incorporation from 1,897±406 to 10,606+1037 cpm (mean±SEM). PTH-(1-34)NH2 at a dose of 10 ng/ml had no significant effect on DNA synthesis. Two separate experiments reproduced these findings. Furthermore, addition of 10 ng/ml PTHrP-(1-141) failed to inhibit [3H]thymidine incorporation in SMC stimulated by 2% or 5% FCS (data not shown).
Discussion
Our studies demonstrate that PTHrP and its mRNA are expressed by vascular smooth muscle cells in primary culture and are markedly and acutely up-regulated when cells are exposed to serum. In confluent, growth-arrested cells PTHrP mRNA was expressed at levels below those observed in growing cells. Time of serum exposure (h) Figure 8 . Detection of PTHrP in SMC conditioned medium by radioimmunoassay. SMC were deprived of serum for 5 d then exposed to 10% FCS. Medium (200 jA) collected at the indicated times was assayed using a PTHrP radioimmunoassay as described in the Methods section. (24, 27) . Our observation is consistent with the recent in vivo studies of the short half-life of PTHrP mRNA in lactating rat mammary gland ( 11) and in vitro observations in human cancer (TT) cells (25) . The extensive 3'-untranslated regions of both rat and human PTHrP mRNA are AU rich and exhibit several AUUUA motifs that could represent structural determinants mediating rapid turnover of PTHrP mRNA (30) . However, in our study cycloheximide had no apparent effect on the constitutive PTHrP expression, which is opposite from previous findings of Ikeda et (25, 26) and in human keratinocytes (32) . Our preliminary studies in SMC show DEX also markedly inhibits the serum induction PTHrP mRNA whereas 1,25-(OH)2D3 is a less effective inhibitor. It is possible that these effects are mediated through classical receptor response elements in the 5' regulatory region of the PTHrP gene, but these have yet to be defined.
The physiological implications ofPTHrP expression in vascular smooth muscle may be considerable in light of the welldocumented effects of both PTH and PTHrP on vascular tone (14) . Both peptides are established vasorelaxants producing hypotensive actions when tested in vivo and in vitro. In addition, we have demonstrated that vasoactive peptides, most notably endothelin, are effective inducers of PTHrP mRNA in quiescent SMC. These findings suggest the intriguing possibility that PTHrP might act as an autocrine factor regulating the state of vessel contractility. Alternatively, PTHrP might function as a local factor, analogous to IGF-I which is known to modulate smooth muscle cell proliferation and differentiation during tissue growth and in response to vascular injury (33) . Our failure to demonstrate an effect of exogenous PTHrP does not preclude a role for this protein in SMC proliferation which might require the presence of other cofactors.
In addition to vascular smooth muscle, increasing evidence suggests that PTHrP has important functions in other smooth muscle tissue. For example, in chicken oviduct, the expression of PTHrP mRNA by the egg shell gland smooth muscle coincides temporally with oviduct development and the arrival of the egg in the shell gland (34) . In addition, other studies have shown that intrauterine occupancy of fetus in the gravid rat placenta triggers PTHrP gene expression in the muscularis layer (35) . Therefore, it is apparent that smooth muscle is a major site of PTHrP production, although its function remains to be established. Moreover, while it is attractive to envision In summary, our studies show for the first time that PTHrP is a major product of normal aortic smooth muscle cells and is regulated in a manner that would suggest a fundamental role in this tissue. The relative abundance of its mRNA in these cells, together with the availability of recently cloned cDNA and genomic DNA probes for this protein should facilitate further study ofthe factors regulating PTHrP expression and the exploration of its possible function in vascular smooth muscle.
